License agreement with an american start-up in the treatment of anaemia and rare genetic disorders.
Erganeo signed an exclusive worldwide licence agreement with GENERAL BIOLOGICS, an American start-up founded in 2016 and based in Cambridge (Massachusetts, USA), on the use of antibody IH4, which improves the specificity of drugs developed by the company and reduces side effects. Two applications are initially under the spotlight: the treatment of anaemia associated with cancer and kidney failure in particular, and rare genetic disorders that can be treated by ‘Protein Replacement Therapy.’
“We are pleased to complete this licensing deal with General Biologics.” said Mr. Suat Topsu, the President of Erganeo. “That's Erganeo's mission: to allow our partner to acquire a major competitive advantage during their growth phase thanks to our technologies!”
Through this licence agreement, Erganeo once again marks its investment in innovations with high medical potential.
Read the press release
